STUDresearch · Non-peptide

Tesofensine

Also known as

NS2330 · NS-2330 · NS 2330 · Tesofensine hydrochloride · Tesofensine HCl · Tesofensine citrate (research-salt discussions) · phenyltropane triple reuptake inhibitor (class talk)

Community talk. May be wrong. Not medical advice. Not a protocol. Not for human or animal use.

Open in the directory ↗

Non-peptide Some talk Systemic Oral Metabolic research compounds

Systemic — an oral monoamine reuptake inhibitor discussed for appetite, food reward and energy balance; not a local or site-specific injection.

What people say Tesofensine is an investigational oral triple monoamine reuptake inhibitor discussed for appetite and weight loss. It is not a peptide, GLP-1 drug or approved US obesity medicine. Doses people talk about

Repeated community amount~0.5 mg (500 mcg) oral once daily

Frequently discussed and used in the reviewed sleep thread; one severe account does not establish how often that response occurs.

TIPO-1 randomized arms0.25, 0.5 or 1.0 mg oral once daily

Separate 24-week trial arms used with an energy-restricted diet; the amounts are not sequential steps.

Phase 3 study arms0.25 or 0.5 mg oral once daily

The later Medix program did not carry the 1.0 mg arm forward.

These are study arms and reports, not a titration ladder. Product identity and milligram-versus-microgram labeling are important uncertainties.

Half-life & effect duration

Half-life in the body: Parent tesofensineAbout 220 hours — roughly 9 days
N-desmethyl metaboliteAbout 374 hours — roughly 16 days
Felt duration people report: Severe wakefulness accountTwo separate 48-hour wake periods
Other sleep accountsRepeated waking, or a helpful sleep-cycle change

Timing context & sources

How it may feel Appetite quieting and dry mouth are common discussion themes. Energy and sleep responses conflict, from focus or easier sleep timing to fragmented sleep and unusually prolonged wakefulness.

Cycles people discuss Trials used continuous once-daily treatment for about 24 weeks. Community cut blocks, washouts and skip-day patterns are separate informal practices, complicated by the long parent half-life. Timing Morning or early-day use is common because sleep disruption can be strong. Slow accumulation over weeks means day-one feel and a missed day are not direct measures of parent elimination. Stacks Diet structure, GLP-1 drugs, caffeine, Cardarine and other metabolic compounds appear in reports. These combinations confound appetite, weight, energy, heart-rate and sleep effects. Access talk RUO capsules, not a peptide vial: 0.25 mg and 0.5 mg oral units dominate. Powder needs a µg-accurate scale — unit mix-ups with other research chems are a QC risk. Labs people mention Resting heart rate is the lab people actually use: TIPO-1 mean ~+7.4 bpm at 0.5 mg. Watch/strap logs; community stop-talk when RHR stays high (threads cite ~90 bpm or +10–15 over baseline — heuristics, not a label). Watch for Long half-life risk: If an AE appears, it may persist or accumulate for days–weeks after dose reduction — unlike short-acting stims that clear overnight.

Tap a line to jump into the full notes. Research only — may be wrong.

Timing context & sources

Half-life in the body

About 220 hours, or roughly 9 days, for parent tesofensine in humans.

A Saniona clinical protocol summarizes human PK as a roughly 220-hour parent half-life and a roughly 374-hour N-desmethyl metabolite half-life; oral exposure and population details are not a felt-effect clock.

The protocol summarizes prior program data rather than reproducing every underlying concentration-time curve; renal impairment can alter exposure and the metabolite is a separate analyte.

Saniona Tesomet clinical study protocol NCT03286829 (opens in a new tab)Protocol page 18, lines 549–568 in the inspected text: approximately 220-hour tesofensine human half-life, 374-hour NS2360 half-life, human population comparisons, oral bioavailability and food context. Full PDF text inspected.Sponsor protocol summarizing earlier PK evidence; it is not the primary publication of every underlying PK study and does not measure subjective appetite or sleep duration.

Felt duration people report

No dependable felt-duration range; even sleep effects in the same discussion were severe, fragmented or described as improved.

One 500 mcg poster described two 48-hour wake periods while feeling clear. A reply described repeated waking and no longer using it on consecutive days, while another reported a helpful sleep-cycle reset.

Small, self-selected reports with unknown product identity and no verified follow-up; 48 hours of wakefulness is one event pattern, not a parent half-life or typical duration.

Lack of need for sleep (opens in a new tab)Read the complete visible post and replies: prince-sword reported 500 mcg since Wednesday and two 48-hour wake periods; mayorjinglejangle reported repeated waking and avoiding consecutive days; bbnov25 reported improved sleep-cycle timing.Three unverified self-reports, no product verification, clinical assessment or visible same-author outcome update; the report cannot establish incidence, safety or a typical effect window.

What people say 21

Appetite / food noise: Community and clinic blogs report smaller meals, fewer snacks, quieter compulsive snacking within days–weeks; confounded by diet coaching. forumanecdote
Cravings / reward: Dopamine-arm story used to explain less “reward eating”; anecdotes of easier deficit adherence. forumanecdote
Oral convenience: Once-daily tablet/capsule with no multi-week inject titration is a major search driver vs semaglutide/tirzepatide. forum
Focus / mood lift (subset): Anecdotes of “dialed in,” motivation, or mild antidepressant-like feel — not a labeled indication; opposite mood AEs also appear at higher doses in trials. anecdotetrial
Vs older orals only: Threads that claim “beats all fat pills” usually mean 2008-era comparators, not head-to-head STEP/SURMOUNT GLP-1 data. forum
Stack confound honesty: Real-world logs often co-credit calorie deficit, GLP-1s, caffeine, cardarine, or other fat-loss agents. forum
2026 r/Tesofensine_ diaries: 0.25 mg for a few days then 0.5 mg is the usual climb. Appetite quiet and dry mouth show up fast; energy/HRV stories split (some Oura HRV up, some RHR +10). forumanecdote
GLP-1 “still hungry / flat” add-on: 2025–26 biohacker posts pitch teso for residual food noise and energy when tirz/reta already quiet the gut. No combo RCT; HR + stim load is the counter. forum
TIPO-1 24-wk mean weight loss (diet + drug): 0.25 / 0.5 / 1.0 mg once daily → ~4.5% / 9.2% / 10.6% vs ~2.0% diet + placebo (p<0.0001); absolute means often cited ~6.7 / 11.3 / 12.8 kg vs ~2.2 kg placebo in ~100 kg baseline obese adults. trial
Placebo-subtracted framing: Community and secondary writeups often quote ~2.5% / 7.2% / 8.6% placebo-subtracted at 0.25 / 0.5 / 1.0 mg — same trial, different presentation. trialforum
0.5 mg sweet spot (trial authors): Interpreted as efficacy close to 1.0 mg with better tolerability; Phase 3 programs dropped 1.0 mg and studied 0.25 / 0.5 mg only. trial
Era comparison (2008): Authors framed 0.5 mg as potential for roughly twice the weight loss of then-approved orals (sibutramine/rimonabant era) — not a head-to-head vs modern GLP-1 Phase 3 packages. trial
Energy expenditure narrative: Acts primarily as appetite suppressant with concurrent talk of higher resting EE / fat oxidation; DIO-rat pair-fed controls returned toward baseline weight while tesofensine held loss — interpreted as possible EE contribution. trialanimal
Animal DIO (Hansen et al. 2010): Oral 1.0 or 2.5 mg/kg × 28 days → ~5.7% and ~9.9% sustained weight loss; hypophagia longer-lasting than sibutramine/rimonabant comparators; improved OGTT insulin response vs pair-feeding alone in that model. animal
Lateral hypothalamus (2024 preclinical): Reports of GABAergic neuron silencing in LH / feeding circuitry — modern mechanism talk beyond simple “reuptake block.” animal
Early neuro meta-signal: In Alzheimer’s/Parkinson’s programs, meta-analysis of 0.125–1.0 mg once daily showed dose-dependent weight loss; ~32% of obese subjects on highest dose achieved ≥5% loss by ~14 weeks. trial
TIPO-4 extension (open-label): After ~3-month washout, prior TIPO-1 completers on 0.5 mg (optional early uptitration to 1.0 mg then back to 0.5) — prior 0.5 mg arm cited for total mean loss ~13–14 kg over ~48 weeks of treatment exposure; prior placebo switchers ~9 kg in first 24 weeks of extension. trial
Phase 3 (Medix, Mexico): ~372-patient program at 0.25 and 0.5 mg daily × 24 weeks; sponsor/partner summaries claim confirmation of Phase 2 efficacy pattern with ~10% mean weight loss talk at the higher dose and favorable safety framing vs Phase 2 — full peer-reviewed primary paper details less widely mirrored in English forums than TIPO-1. trialforum
Regulatory path (Mexico): Medix NDA to COFEPRIS; February 2023 technical-committee favorable opinion reported by Saniona for obesity/weight management — not a US FDA approval. trial
Lean-mass talk: Trial framing and some DEXA-ish community logs claim favorable fat-vs-lean ratio for the size of loss; individual body-comp logs still vary and are stack-confounded. trialforum
Body composition (trial framing): Decreases in body fat and waist circumference reported alongside weight; modest lipid improvements discussed in summaries. trial

Doses people talk about 18

Modal community target: ~0.5 mg (500 mcg) once daily is the most repeated practical target — matches the efficacy/tolerability “sweet spot” language from TIPO-1. forumtrial
Start / low band: 0.25 mg (250 mcg) once daily for 1–4 weeks to gauge dry mouth, sleep, resting HR, and mood before any step-up. forum
Upper caution: 1.0 mg trial arm had more AEs (including BP signal and more depressed-mood reports); many research-chem and clinic writeups actively discourage casually matching 1.0 mg. trialforum
Microgram language: Same doses spoken as 250 / 500 / 1000 mcg — unit confusion with other research chems is a real QC risk when buying powder. forum
EOD / skip-day start (anecdote): Because t½ is multi-day, some users start every other day or alternate 0.25 mg patterns to feel accumulation before daily 0.5 mg — not a trial schedule. anecdoteforum
Timing: Morning (or early day) preferred almost universally to cut insomnia risk; with or without food in trial-style talk. forumtrial
Missed dose logic (community): Do not double next day — long half-life already covers gaps better than short-acting stims. forum
Vendor formats discussed: Finished 0.25 mg and 0.5 mg capsules/tablets most common; research powder (requires µg-accurate scale) and minority research liquids/droppers also appear — identity and content uniformity are the main risks. forum
Potency uncertainty: Gray-market labels may not match delivered mcg/mg without independent testing; unexpected sides or nulls often blamed on under/over-fill. forum
2026 community protocol still 0.25 → 0.5: Start 0.25 mg daily 1–2 (sometimes 2–4) weeks, then 0.5 mg. 1.0 mg stays the “more HR/mood, not much more loss” arm people are told not to chase. forumtrial
Do not double a missed day: Long t½ already covers gaps. Doubling is how people meet the 1.0 mg AE profile by accident. forum
Titration pattern (community): Hold 0.25 mg for ~2–4 weeks → step to 0.5 mg if tolerated; long half-life means do not judge a step change after only a few days. forum
Framing: Research exposures, trial arms, and community-discussed ranges only — not medical advice, not prescriptions, not a recommendation to consume. forumtrial
TIPO-1 trial arms: 0.25 mg, 0.5 mg, and 1.0 mg oral once daily for 24 weeks plus energy-restricted diet (often described as ~300 kcal deficit + activity coaching). trial
Phase 3 (Medix) arms: 0.25 mg and 0.5 mg oral once daily (1.0 mg not carried forward). trial
Early program band: Neuro programs also explored ~0.125–1.0 mg once daily oral in meta-analyzed weight-loss signals. trial
Tesomet fixed combo (related clinical form): Tesofensine 0.5 mg + metoprolol 50 mg once daily in hypothalamic-obesity Phase 2 work — separate product intent (HR mitigation), not plain tesofensine. trial
Animal doses (not human): DIO rat oral ~1.0–2.5 mg/kg/day in 28-day work — do not scale naively to human capsule mg. animal

How it may feel 10

First days (sensitive users): Reports include early appetite quieting, dry mouth or a wired/focusy feel. In one 500 mcg account, the poster stayed awake for two 48-hour stretches while feeling clear and not tired; one reply described repeated waking and avoiding consecutive days, while another said sleep timing improved. forumanecdote
Days 1–7: Appetite drop + xerostomia often lead the subjective list; HR awareness and sleep quality become early checkpoints. forumtrial
Weeks 1–2: Steadier hunger control and fewer snack thoughts; deficit adherence reportedly easier if diet structure is already present. forum
Weeks 3–6: Long half-life build — many call this the window when “full effect” emerges; weight trend and resting HR are better judges than day-1 feel. forum
Steady-state talk: Forums and dosing guides often say 4–6 weeks (sometimes ~8 weeks / ~2 months) of daily dosing before plasma levels fully stabilize given ~9-day parent half-life. forumtrial
Weeks 8–12: Progressive loss if calories stay controlled; plateaus more often blamed on diet creep / NEAT drop than “need 1 mg.” forum
Build-then-flat (2026): Perimenopause and r/Tesofensine_ logs describe a few good weeks at 0.5 mg then tired/flat, then a couple days off because the ~9-day half-life is still covering. Not a trial schedule. forumanecdote
Dry mouth week 1–3: Still the loudest feel. Water, gum, chapped-lips posts. forum
Months 3–6: Matches the 24-week TIPO-1 horizon communities use as the primary reference block. trial
Extension horizon: Multi-month / ~48-week open-label TIPO-4 continuity is cited when people discuss staying on longer than 24 weeks. trial

Around the dose 6

Clock: Morning or early-day use dominates discussion because insomnia can be pronounced, but experiences vary: one reviewed 500 mcg account described two 48-hour wake periods, one reply reported fragmented sleep, and another said sleep timing improved. These reports do not establish a universal clock. forum
Food: With or without. Food if the first-week nausea shows; no GH-peptide fasting rule. forum
Training: Watch heart rate on cardio. Trial +7.4 bpm at 0.5 mg is the number people put next to a chest strap. trialforum
After: Water and sugar-free gum for dry mouth. Do not judge a dose step after two days — steady state is weeks. forumtrial
Skip-day folklore: Because t½ is ~9 days, some take a couple days off when they feel flat rather than dropping the mg. Irregular intake makes AE attribution harder. forum
Avoid: Extra caffeine/yohimbine piles, late dosing, and jumping 0.25 → 1.0 because “it’s not working yet.” forum

Cycles people discuss 9

No evidence-based “blast/cruise” cycle: Dosing guides emphasize there is no established on–off sports-style protocol; continuous exposure is what was studied. forumtrial
Short community blocks: 8–12 week oral runs for cut phases, product tests, or tolerance probes are common outside trials. forum
Medium community blocks: ~16–24 weeks to roughly match the primary RCT horizon before reassessing. forum
Longer talk: Multi-month stays with BP/HR/mood self-monitoring; not approved chronic labeling in the US. forum
Washout between runs: Half-life ~days → plan multi-week off (forums often ~4–8+ weeks) rather than a same-week reset; TIPO-4 re-enrollment averaged ~3 months off after TIPO-1. trialforum
Re-runs: Seasonal fat-loss reuse appears in logs; multi-year continuous gray-market safety data are not established. forum
Stop rules (community heuristics): Persistent insomnia, resting HR climb that feels excessive, BP rise, anxiety/depression, or null weight trend despite verified diet — pause and reassess rather than dose-up. forum
Trial pattern = continuous daily: TIPO-1 dosed once daily for 24 weeks without on/off cycling; Phase 3 similarly continuous 24-week treatment. trial
TIPO-4 continuity: Open-label extension after washout supports multi-month continuous exposure discussion (interim ~24-week extension data on top of prior TIPO-1). trial

Timing 11

Steady state: Slow build over weeks of daily dosing; full response and full side-effect profile should not be judged after a handful of doses. forumtrial
Why EOD debates exist: Some argue multi-day coverage means skip-days still leave active levels; others warn irregular intake makes AE attribution and steady-state math harder. forum
CYP3A4 interaction awareness: Strong inhibitors/inducers could theoretically alter levels; community flags this as a research caution, not a mapped interaction table for every drug. forumtrial
After levels fall: Appetite return over weeks; some claim residual habit/skill from the quiet-appetite window. anecdote
Washout estimate: Forums often treat multi-week (sometimes ~1–2 months) clearance for practical “off” planning — informal, not personal therapeutic drug monitoring. forum
Downstream feel lag: Weight-trend changes track cumulative deficit + weeks of exposure more than single-dose peaks. forum
Parent elimination half-life: ~220 hours (~9 days) — central PK fact that drives almost all dosing culture. trial
Oral bioavailability: ~90% cited for the oral small molecule — supports capsule route dominance. trial
Metabolite M1 (NS2360): Formed mainly via CYP3A4 N-dealkylation; only metabolite readily detected in human plasma; t½ ~374 hours (~16 days); exposure ~31–34% of parent at steady state; in vivo contribution estimated ~6% of parent activity. trial
Renal role: Kidney clearance of parent is minor (~15–20%); hepatic CYP3A4 is the main metabolic path discussed. trial
Dosing logic vs half-life: Still once-daily oral in all major trials — not weekly depot — despite multi-day half-life (daily dosing builds and holds steady state). trial

Stacks 13

Diet first: Structured calorie deficit + protein + steps/cardio is credited whenever community outcomes look trial-like; TIPO-1 co-prescribed energy restriction. trialforum
GLP-1 / dual / triple agonists: Semaglutide, tirzepatide, retatrutide — sequential or overlapping use is heavily discussed: teso for central food-noise, GLP-1 for peripheral satiety/gastric emptying. No controlled synergy RCTs; additive nausea/HR/sleep risk is the counter-argument. forum
Sema fatigue rescue narrative: Anecdotes of adding low-dose teso when GLP-1 fatigue or residual hunger remains — confounded and unsupervised in research-chem contexts. anecdote
Caffeine / classic stims: Occasional co-use for training energy; watch cumulative HR, BP, and insomnia (monoamine + stim stack). forum
Cardarine / endurance orals: Named together in athletic cut stacks — attribution heavily confounded; different risk classes (PPARδ cancer lore vs monoamine CV lore). forum
5-Amino-1MQ / NNMT orals: Appears in multi-agent “metabolic stack” blogs with teso as the appetite lever. forum
Other research orals: Occasional mention with AOD-9604, Frag 176-191, or SARM cut agents — multi-variable logs. forumanecdote
DIY beta-blocker talk: Forums sometimes echo Tesomet’s rationale; self-combining cardiovascular drugs is a high-risk research-chem behavior and is not trial-supported for unsupervised use. forum
Monitoring “stack”: Resting HR (watch/strap), home BP cuff, sleep log, and mood check-ins are repeatedly framed as more important than adding more compounds. forum
Avoid pile-on monoamines: Historical caution vs stacking with sibutramine-class agents, high-dose SNRIs/stimulants, or other TRIs without understanding additive CV/neuropsychiatric load. forumtrial
BioFlow-style blend talk: Vendor SKUs pair tesofensine with magnesium L-threonate and taurine and pitch taurine for HR/jitters. That is a shop recipe, not Tesomet (teso + metoprolol). forum
Taurine / mag as “sides cover”: 2026 Jay-shop copy says the blend is for people who felt solo teso. Uncontrolled. forum
Tesomet logic (formal): Fixed tesofensine 0.5 mg + metoprolol 50 mg studied to blunt HR/BP signal while keeping weight-loss efficacy in special populations (e.g., hypothalamic obesity Phase 2: additional ~−6.3% vs placebo at 24 weeks without mean HR/BP rise in that small trial). trial

Access talk 5

RUO capsules, not a peptide vial: 0.25 mg and 0.5 mg oral units dominate. Powder needs a µg-accurate scale — unit mix-ups with other research chems are a QC risk. forum
BioFlow / blend SKUs: 2025–26 shops stopped some solo teso bottles and sold tesofensine + magnesium L-threonate + taurine as the “sides” product. Still RUO, still not Tesomet. forum
Mis-shelved as a peptide: Vendor SEO puts it next to GLP vials. Chemistry is a small-molecule reuptake inhibitor. forum
Not US-approved: Investigational obesity TRI. Mexico Medix/COFEPRIS path and a 2023 technical-committee opinion are the regulatory story, not an FDA label. trial
Tesomet is a different product: 0.5 mg tesofensine + 50 mg metoprolol in hypothalamic-obesity trials. DIY beta-blocker stacking is not that study. trial

Labs people mention 4

Resting heart rate is the lab people actually use: TIPO-1 mean ~+7.4 bpm at 0.5 mg. Watch/strap logs; community stop-talk when RHR stays high (threads cite ~90 bpm or +10–15 over baseline — heuristics, not a label). trialforum
Mood / sleep diary: Psychiatric AEs clustered at 1.0 mg in a pre-screened trial population. Real-world mood watch is the other half of HR. trialforum
Not a lipid-first drug: Scale + appetite + RHR beat a cholesterol panel for what this compound is discussed as. forum
Blood pressure: Did not rise vs placebo at 0.25/0.5 mg in TIPO-1; it did at 1.0 mg. Home cuff still shows up in cautious logs. trial

Storage notes 2

No mix instructions here: STUDresearch does not list reconstitution, diluent volumes, or syringe unit charts. People reconstitute many different ways and vial labels differ — that content creates more confusion than clarity. forum
Storage (general talk only): Unopened research products are usually kept cool, dry, and away from light per the seller label. Anything after first use is product-specific — follow the label, not a universal forum SOP. forum

Related 8

Watch for 20

Insomnia: Trial + user reports; clearly worse with later-day dosing; morning-only schedules dominate mitigation talk. trialforum
CV class history: Sibutramine-era cardiovascular withdrawals and regulator caution are repeatedly invoked; US/EU advancement has been limited by CV-outcomes expectations beyond Phase 2/3 weight loss. trialforum
Psychiatric / mood: Depressed mood reported in ~6.1% on highest (1.0 mg) dose vs 0% placebo in TIPO-1 analyses — in a population pre-screened against known psychiatric disorders; anxiety, restlessness, and wired-but-tired appear in community logs. trialforum
Overstimulation: Minority but recurring: jitter, elevated resting HR feel, difficulty winding down. forum
Long half-life risk: If an AE appears, it may persist or accumulate for days–weeks after dose reduction — unlike short-acting stims that clear overnight. forumtrial
Withdrawal / rebound appetite: Not classic benzo-style withdrawal lore; main post-stop issue is return of hunger and possible weight regain. forum
Source / gray-market risk: Mislabeling, under/over-potent tablets, contaminants, and “tesofensine peptide” marketing independent of trial-grade material. forum
Drug-interaction caution: CYP3A4 path + monoamine mechanism → community flags combining with MAOIs, other strong serotonergic/stimulant stacks, or unmonitored polypharmacy. forumtrial
Special populations: Not characterized as pediatric therapy; pregnancy and complex cardiac disease are common absolute research-only red flags in clinic writeups. forumtrial
Not risk-free: Appetite and scale wins coexist with dry mouth, sleep, HR, and mood cautions; one clean 8-week log ≠ long-term cardiovascular or psychiatric safety. forumtrial
Long t½ trap: If insomnia, HR, or mood go bad, they can linger days–weeks after a cut. 2026 skip-day logs exist because of that lag. forumtrial
GLP stack HR: Adding teso to tirz/reta for energy can stack pulse and sleep loss on top of GLP fatigue — the 2026 “smart fat burner” pitch does not have a combo safety file. forum
Dry mouth (xerostomia): Top trial AE and most common community complaint; dose-dependent pattern noted in summaries (placebo-subtracted rates reported in ranges up to high tens of percent at higher doses). trial
GI: Nausea, constipation, hard stools, and diarrhoea all listed among common TIPO-1 AEs. trial
Headache: Frequently listed among common AEs in secondary trial summaries. trial
Heart rate: Mean ~+7.4 bpm at 0.5 mg vs placebo at 24 weeks in TIPO-1 (p=0.0001); ~+8 bpm class talk at 1.0 mg in secondary sources — primary cardiovascular discussion point. trial
Blood pressure: No significant SBP/DBP increase vs placebo at 0.25 and 0.5 mg in TIPO-1; BP rose at 1.0 mg — major reason 1.0 mg was de-emphasized. Secondary sources also note small diastolic/BP shifts in dose-dependent patterns across the program. trial
Abuse-liability discussion: DAT activity raises theoretical stimulant-abuse questions; published commentary notes less reliable self-administration/stereotypy than classic DA appetite suppressants at therapeutic exposures — still a research caution, not a green light. trial
Evidence honesty: Stronger human RCT package than most research chems (Phase 2b + extension + regional Phase 3), but still not a substitute for large outcomes trials or US-approved labeling; cross-trial GLP-1 comparisons are confounded by duration, population, and co-interventions. trial
1.0 mg is the AE arm: BP rise and more depressed-mood reports in TIPO-1 are why Phase 3 and forum charts dropped it. trial

Updated: 2026-09-01

Evidence mix Mixed trial + community tags Full: every bullet (trial + community). Use Scan for a faster bro-science read.

↑ Back to top

Half-life & effect duration

Timing context & sources⌄

Half-life in the body

Felt duration people report

What people say 21

Doses people talk about 18

How it may feel 10

Around the dose 6

Cycles people discuss 9

Timing 11

More on what it is 9

Stacks 13

Access talk 5

Labs people mention 4

Storage notes 2

Related 8

Watch for 20

Timing context & sources